News & Resources
The Cancer Immunotherapy Consortium embraces communication and collaboration among its members and among other like-minded associations that strive to bring effective immune-based cancer treatments to more patients.
CIC members contribute to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
We invite you to browse our library of publications, news releases, and e-newsletters.
-
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.
April 23, 2013
-
The Association for Cancer Immunotherapy Immunoguiding Program and the Cancer Immunotherapy Consortium of the Cancer Research Institute today announced a publication discussing the results of a unique collaborative vetting process which has now led to publication guidelines that increase transparency of immune response assessments.
July 25, 2012
-
The Association for Cancer Immunotherapy Immunoguiding Program and the Cancer Immunotherapy Consortium of CRI published a joint paper discussing recent results of independent international, cross-laboratory immune assay harmonization studies.
November 8, 2011
-
Drs. James P. Allison, chair of the immunology program at Memorial Sloan-Kettering Cancer Center, and Axel Hoos, medical lead in immunology/oncology at Bristol-Myers Squibb, have been named directors of the CRI Cancer Immunotherapy Consortium (CIC), the premier academic-industry association dedicated to accelerating development of safe and effective cancer immunotherapies to patients.
November 7, 2011
-
The Cancer Immunotherapy Consortium of the Cancer Research Institute and the Association for Cancer Immunotherapy have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.
October 17, 2011